Tools


Site Haritası

Site Haritası

PET/CT: First-line Restaging Modality in Patients With Suspected Metastatic Breast Cancer Recurrence

Author: A Dirisamer, B.S. Halpern, D Flöry, F Wolf, M Beheshti, M.E. Mayerhoefer and W Langsteger

The study performs diagnostic enhanced CT and 18F FDG PET in one investigation, proving modality sensitivity and determining its diagnostic value in restaging breast cancer recurrence. This shows PET/CT can improve staging and alter therapeutic options.

*FLUDEOXYGLUCOSE F 18 INJECTION

For Intravenous Use

 

INDICATIONS AND USAGE
Fludeoxyglucose F 18 injection (18F FDG) is indicated for positron emission tomography (PET) imaging in the following settings:

 

Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.

 

Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.

 

Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.

 

IMPORTANT SAFETY INFORMATION
Radiation Risks: Radiation-emitting products, including fludeoxyglucose F 18 injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.

 

Blood Glucose Abnormalities: In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to fludeoxyglucose F18 injection administration.

 

Adverse Reactions: Hypersensitivity reactions with pruritus, edema and rash have been reported; have emergency resuscitation equipment and personnel immediately available.

 

Siemens' PETNET Solutions is a manufacturer of Fludeoxyglucose F18 Injection (18F FDG). Indication and important safety information as approved by the US Food and Drug Administration can be found at the links below for 18F FDG, adult dose 5-10 mCi, administered by intravenous injection.

Date: 01-02-2010


Abstracts

Bu bilgi yardımcı oldu mu?
Yanıtınız için teşekkür ederiz
Yorumunuzda sayı ve/veya '@' işareti olduğunu fark ettik. Sizinle iletişime geçmemiz için telefon numarası ya da e-posta adresi girmeye çalışıyorsanız lütfen bizimle e-posta formumuz aracılığıyla iletişime geçiniz.

Not: Doğrudan kişisel bir yanıt almak için lütfen bizimle e-posta formumuz üzerinden iletişime geçiniz.

Teşekkür ederiz